Inhaled formulations and pulmonary drug delivery systems for respiratory infections

Zhou, Qi Tony; Leung, Sharon Shui Yee; Tang, Patricia A.; Parumasivam, Thaigarajan; Loh, Zhi Hui; Chan, Hak‐Kim

doi:10.1016/j.addr.2014.10.022

Cited by 210 publications

(131 citation statements)

References 197 publications

Supporting

Mentioning

128

Contrasting

Order By: Relevance

“…It is formulated as a dry powder aerosol for delivery using Diskhaler technology [126] (reviewed in [19,20]). The highly hydrophilic, charged nature of zanamivir is not "drug-like" in terms of features for an orally active drug, and bioavailability is only around 2% when the drug is given orally [132].…”

Section: Mode Of Administration Of the Highly Polar Drugmentioning

confidence: 99%

“…Infection of the respiratory tract makes administration of drugs by inhalation advanta geous. Inhaled administration of drug in an aerosolized or dry powder form not only delivers drug rapidly to the site of infection in the respiratory tract but also avoids first-pass metabolism and systemic burden of drug on unaffected tissues and organs [19,20]. Inhaled delivery has an added advantage of enhancing the bioavailability of drugs with poor oral absorption [19].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Development of Influenza Virus Sialidase Inhibitors

Pascolutti

Thomson

Itzstein

2016

Methods and Principles in Medicinal Chemistry

View full text Add to dashboard Cite

Section: Mode Of Administration Of the Highly Polar Drugmentioning

confidence: 99%

mentioning

confidence: 99%

Development of Influenza Virus Sialidase Inhibitors

Pascolutti

Thomson

Itzstein

2016

Methods and Principles in Medicinal Chemistry

View full text Add to dashboard Cite

“…As discussed above, formulation of antibiotics into liposomes has the potential to provide once-daily treatment regimens [1,5,[8][9][10]19,[28][29][30][31][32][39][40][41][42]. Pulmaquin, which is a mixture of unencapsulated and liposomally encapsulated ciprofloxacin, provides a kinetic profile with a rapid peak of ciprofloxacin followed by the long tail characteristic of release from the liposomally encapsulated component [39].…”

Section: Future Scenarios For Inhaled Antibiotic Treatment Optionsmentioning

confidence: 99%

“…Mixing or rotating antibiotics with different mechanisms of action has been used in clinical practice with the hope for better patient outcome [5].…”

mentioning

confidence: 99%

Emerging Opportunities for Inhaled Antibiotic Therapy

Cipolla¹,

Froehlich²,

Gonda³

2015

J Antimicro

View full text Add to dashboard Cite

Inhaled antibiotics have become a mainstay of cystic fibrosis (CF) therapy by providing high drug concentrations locally in the lung while minimizing systemic exposure and thus the potential for side effects. In CF, inhaled antibiotics decrease the rate of decline of lung function, improve the quality of life, and reduce the frequency of exacerbations and hospital admissions. However, the burden of therapy remains high in CF. There is an opportunity for more convenient and effective inhaled antibiotics to reduce the disease burden in CF. In contrast, despite the unmet medical need, no inhaled antibiotics are approved for lung infections in a number of other diseases including non-CF bronchiectasis, COPD, melioidosis, pneumonic plague, anthrax, Q fever, tularemia and patients with other infections including non-tuberculous mycobacteria. This review discusses the progress towards achieving that goal in those indications. Additionally, the approved inhaled antibiotics in CF are only available as a fixed dose that is inhaled twice or thrice daily. There is a limited opportunity to personalize therapy to the patient. This review envisions a future scenario where the treatment of lung infections can be optimized to the specific needs of each individual based on the attributes of their infectious agents.

show abstract

“…The conventional inhalation products have high dosing frequency and large dose often leads to local and systemic toxicity. Therefore, novel controlled release carrier systems may provide a possible solution to these problems by reducing dosing frequency and increasing drug bioavailability [5] . The decrease in dosing frequency and side effects can lead to improved patient compliance and therefore, it can resolve the problem of nonadherence to prescribed therapy which acts as one of the major obstacle in the control of various respiratory and non-respiratory diseases [6] .…”

mentioning

confidence: 99%

Current Development in the Evaluation Methods of Pulmonary Drug Delivery System

Shaji¹,

Shaikh²

2016

pharmaceutical-sciences

View full text Add to dashboard Cite

Shaji and Shaikh: Current Development of Pulmonary Drug DeliveryThe pulmonary drug delivery system offers several merits over other drug delivery systems and therefore, this delivery route has been in prime focus for various applications like local and systemic therapeutics delivery. The overall development of drug delivery system depends on its efficacy, quality and safety and to achieve such attributes there is a need of reliable evaluation methods to test them. This review provides an in-depth analysis of the development in the evaluation of pulmonary drug delivery systems. In vitro methods of testing pulmonary products such as particle morphological studies, powder flow characteristics, moisture content test, aerosol turboelectric characterization, particles interparticulate forces measurement and solid state characterizations were discussed. Particle size and zeta potential measurement and evaluation of aerosol performance such as dose uniformity and aerodynamic particle size distribution were reviewed in detail. The development of dissolution methods for pulmonary products is also elaborated. Various cell culture methods for testing pulmonary products were overviewed. The in vivo testing methods including drug administration systems, drug deposition studies and pharmacokinetic studies and ex vivo testing models were also highlighted. Together an overview of current advancement in evaluation and characterization of pulmonary drug delivery system can be analyzed and studied through this review.

show abstract

Inhaled formulations and pulmonary drug delivery systems for respiratory infections

Cited by 210 publications

References 197 publications

Development of Influenza Virus Sialidase Inhibitors

Development of Influenza Virus Sialidase Inhibitors

Emerging Opportunities for Inhaled Antibiotic Therapy

Current Development in the Evaluation Methods of Pulmonary Drug Delivery System

Contact Info

Product

Resources

About